Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,017 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trypanosoma vivax in and outside cattle blood: Parasitological, molecular, and serological detection, reservoir tissues, histopathological lesions, and vertical transmission evaluation.
de Melo-Junior RD, Bastos TSA, Couto LFM, Cavalcante ASA, Zapa DMB, de Morais IML, Heller LM, Salvador VF, Leal LLLL, Franco AO, Miguel MP, Ferreira LL, Cadioli FA, Machado RZ, Lopes WDZ. de Melo-Junior RD, et al. Among authors: miguel mp. Res Vet Sci. 2024 May 6;174:105290. doi: 10.1016/j.rvsc.2024.105290. Online ahead of print. Res Vet Sci. 2024. PMID: 38776695
Prospective study for the early detection of lung carcinoma in patients with HIV infection (GESIDA study 8815).
Valencia ME, Pirogova T, Romera D, Montero M, Tasías M, Sanz J, Arranz A, Vergas J, Tellez MJ, Fanjul F, Campins A, Cervero M, Jarrín I, de Miguel M, Martín Carbonero L, Yllescas M, González J. Valencia ME, et al. Among authors: de miguel m. Enferm Infecc Microbiol Clin (Engl Ed). 2024 May 11:S2529-993X(24)00124-2. doi: 10.1016/j.eimce.2024.05.005. Online ahead of print. Enferm Infecc Microbiol Clin (Engl Ed). 2024. PMID: 38735831
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C; DESTINY-PanTumor01 study group. Li BT, et al. Among authors: de miguel m. Lancet Oncol. 2024 May 3:S1470-2045(24)00140-2. doi: 10.1016/S1470-2045(24)00140-2. Online ahead of print. Lancet Oncol. 2024. PMID: 38710187
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V. Prenen H, et al. Among authors: de miguel m. Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677. Online ahead of print. Clin Cancer Res. 2024. PMID: 38709220
1,017 results